Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Other(1)

Detailed Status

Completed3
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

completed375%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs

NCT05429476
unknown

Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism

NCT05512702
completedphase_3

Extending the Time for Thrombolysis in Emergency Neurological Deficits

NCT00887328
completedphase_3

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

NCT01580839

Clinical Trials (4)

Showing 4 of 4 trials
NCT05429476Phase 3

EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs

Completed
NCT05512702

Reduced Dose Thrombolytic in Intermediate/High Risk Pulmonary Thromboembolism

Unknown
NCT00887328Phase 3

Extending the Time for Thrombolysis in Emergency Neurological Deficits

Completed
NCT01580839Phase 3

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4